Review of Evidence of RAT Benefit in IR Patients or Patients With Risk Modifiers from 2008 to 2011, No Evidence of Benefit
| First Author, Year (Ref) . | Design . | Population . | Non-RAT- Treated, % . | Risk Stratification . | Event No. . | F/U Tools (Median F/U) . | Results . |
|---|---|---|---|---|---|---|---|
| Pelttari, 2008 (58) | RSC | 495 DTC (median age, 40.6 y); 7% T4, 12.5% N1, 0.2% M1 | 20 | MACIS stage | Cancer death,1 (0.2%); recurrences, 44 (8%) | Tg and neck US (11.6 y, range 5–19) | No difference in RAT- and non-RAT-treated for tumor recurrence (P = .8). Independent risk factors of recurrence: age, gender, and local infiltration |
| Hay, 2008 (59) | RSC | 900 mPTC (mean age, 46 y), pT1a, 30% N1, 3% M1 | 87 | No | Cancer death, 3 (0.3%); 40 y recurrence rate, 8% | NA (17.2 y, range 0.1–54) | No significant improvement in RAT- vs non-RAT-treated patients for local and distant recurrence (P = .34 and P = .84, respectively). Recurrence more likely in multifocal tumors (11 vs 4%; P = .002) and N1 patients (16 vs 0.8%; P < .001), but no effect of RAT |
| Ross, 2009 (60) | Registry | 611 mPTC (46% < 45 y old); pT1a, 22% N1 | 56 | N1 and multifocality | Cancer death,1 (<0.1%); recurrences, 38 (6%) | Tg + imaging (3 y, range 0–18) | No significant improvement in RAT- vs non-RAT-treated patients for recurrence, even after adjusting for N1 status and multifocality. In the non-RAT-treated group, recurrence was more frequent in multifocal mPTC (P = .02) |
| Ito, 2010 (61) | RSC | 2638 PTC (mean age, 51 y); cT1 cN0, 26% T3, 57% N1 | 100 | TNM | Cancer death,1 (< 0.1%); recurrences, 62 (2%) (4 M1) | Tg + imaging (CRx, US, CT scan) (7.5 y, range 0.5–20) | 10-y DFS, 97%; 10-y DFS in N1 patients, 96%; recurrence rate, 2%; 1% thyroid bed recurrence in patients treated with lobectomy |
| Vaisman, 2011 (43) | RSC | 289 DTC (median age, 44 y) 10% T3, 7% N1a, 2% N1b | 100 | ATA | Recurrences, 8 (3%) | Tg + neck US (5 y, range 0.5–34) | Very low rate of recurrence: 2.3% with total thyroidectomy and 4% with lobectomy |
| First Author, Year (Ref) . | Design . | Population . | Non-RAT- Treated, % . | Risk Stratification . | Event No. . | F/U Tools (Median F/U) . | Results . |
|---|---|---|---|---|---|---|---|
| Pelttari, 2008 (58) | RSC | 495 DTC (median age, 40.6 y); 7% T4, 12.5% N1, 0.2% M1 | 20 | MACIS stage | Cancer death,1 (0.2%); recurrences, 44 (8%) | Tg and neck US (11.6 y, range 5–19) | No difference in RAT- and non-RAT-treated for tumor recurrence (P = .8). Independent risk factors of recurrence: age, gender, and local infiltration |
| Hay, 2008 (59) | RSC | 900 mPTC (mean age, 46 y), pT1a, 30% N1, 3% M1 | 87 | No | Cancer death, 3 (0.3%); 40 y recurrence rate, 8% | NA (17.2 y, range 0.1–54) | No significant improvement in RAT- vs non-RAT-treated patients for local and distant recurrence (P = .34 and P = .84, respectively). Recurrence more likely in multifocal tumors (11 vs 4%; P = .002) and N1 patients (16 vs 0.8%; P < .001), but no effect of RAT |
| Ross, 2009 (60) | Registry | 611 mPTC (46% < 45 y old); pT1a, 22% N1 | 56 | N1 and multifocality | Cancer death,1 (<0.1%); recurrences, 38 (6%) | Tg + imaging (3 y, range 0–18) | No significant improvement in RAT- vs non-RAT-treated patients for recurrence, even after adjusting for N1 status and multifocality. In the non-RAT-treated group, recurrence was more frequent in multifocal mPTC (P = .02) |
| Ito, 2010 (61) | RSC | 2638 PTC (mean age, 51 y); cT1 cN0, 26% T3, 57% N1 | 100 | TNM | Cancer death,1 (< 0.1%); recurrences, 62 (2%) (4 M1) | Tg + imaging (CRx, US, CT scan) (7.5 y, range 0.5–20) | 10-y DFS, 97%; 10-y DFS in N1 patients, 96%; recurrence rate, 2%; 1% thyroid bed recurrence in patients treated with lobectomy |
| Vaisman, 2011 (43) | RSC | 289 DTC (median age, 44 y) 10% T3, 7% N1a, 2% N1b | 100 | ATA | Recurrences, 8 (3%) | Tg + neck US (5 y, range 0.5–34) | Very low rate of recurrence: 2.3% with total thyroidectomy and 4% with lobectomy |
Abbreviations: CRx, chest radiography; DSS, disease-specific survival; NA, not available; RSC, retrospective single center.
Review of Evidence of RAT Benefit in IR Patients or Patients With Risk Modifiers from 2008 to 2011, No Evidence of Benefit
| First Author, Year (Ref) . | Design . | Population . | Non-RAT- Treated, % . | Risk Stratification . | Event No. . | F/U Tools (Median F/U) . | Results . |
|---|---|---|---|---|---|---|---|
| Pelttari, 2008 (58) | RSC | 495 DTC (median age, 40.6 y); 7% T4, 12.5% N1, 0.2% M1 | 20 | MACIS stage | Cancer death,1 (0.2%); recurrences, 44 (8%) | Tg and neck US (11.6 y, range 5–19) | No difference in RAT- and non-RAT-treated for tumor recurrence (P = .8). Independent risk factors of recurrence: age, gender, and local infiltration |
| Hay, 2008 (59) | RSC | 900 mPTC (mean age, 46 y), pT1a, 30% N1, 3% M1 | 87 | No | Cancer death, 3 (0.3%); 40 y recurrence rate, 8% | NA (17.2 y, range 0.1–54) | No significant improvement in RAT- vs non-RAT-treated patients for local and distant recurrence (P = .34 and P = .84, respectively). Recurrence more likely in multifocal tumors (11 vs 4%; P = .002) and N1 patients (16 vs 0.8%; P < .001), but no effect of RAT |
| Ross, 2009 (60) | Registry | 611 mPTC (46% < 45 y old); pT1a, 22% N1 | 56 | N1 and multifocality | Cancer death,1 (<0.1%); recurrences, 38 (6%) | Tg + imaging (3 y, range 0–18) | No significant improvement in RAT- vs non-RAT-treated patients for recurrence, even after adjusting for N1 status and multifocality. In the non-RAT-treated group, recurrence was more frequent in multifocal mPTC (P = .02) |
| Ito, 2010 (61) | RSC | 2638 PTC (mean age, 51 y); cT1 cN0, 26% T3, 57% N1 | 100 | TNM | Cancer death,1 (< 0.1%); recurrences, 62 (2%) (4 M1) | Tg + imaging (CRx, US, CT scan) (7.5 y, range 0.5–20) | 10-y DFS, 97%; 10-y DFS in N1 patients, 96%; recurrence rate, 2%; 1% thyroid bed recurrence in patients treated with lobectomy |
| Vaisman, 2011 (43) | RSC | 289 DTC (median age, 44 y) 10% T3, 7% N1a, 2% N1b | 100 | ATA | Recurrences, 8 (3%) | Tg + neck US (5 y, range 0.5–34) | Very low rate of recurrence: 2.3% with total thyroidectomy and 4% with lobectomy |
| First Author, Year (Ref) . | Design . | Population . | Non-RAT- Treated, % . | Risk Stratification . | Event No. . | F/U Tools (Median F/U) . | Results . |
|---|---|---|---|---|---|---|---|
| Pelttari, 2008 (58) | RSC | 495 DTC (median age, 40.6 y); 7% T4, 12.5% N1, 0.2% M1 | 20 | MACIS stage | Cancer death,1 (0.2%); recurrences, 44 (8%) | Tg and neck US (11.6 y, range 5–19) | No difference in RAT- and non-RAT-treated for tumor recurrence (P = .8). Independent risk factors of recurrence: age, gender, and local infiltration |
| Hay, 2008 (59) | RSC | 900 mPTC (mean age, 46 y), pT1a, 30% N1, 3% M1 | 87 | No | Cancer death, 3 (0.3%); 40 y recurrence rate, 8% | NA (17.2 y, range 0.1–54) | No significant improvement in RAT- vs non-RAT-treated patients for local and distant recurrence (P = .34 and P = .84, respectively). Recurrence more likely in multifocal tumors (11 vs 4%; P = .002) and N1 patients (16 vs 0.8%; P < .001), but no effect of RAT |
| Ross, 2009 (60) | Registry | 611 mPTC (46% < 45 y old); pT1a, 22% N1 | 56 | N1 and multifocality | Cancer death,1 (<0.1%); recurrences, 38 (6%) | Tg + imaging (3 y, range 0–18) | No significant improvement in RAT- vs non-RAT-treated patients for recurrence, even after adjusting for N1 status and multifocality. In the non-RAT-treated group, recurrence was more frequent in multifocal mPTC (P = .02) |
| Ito, 2010 (61) | RSC | 2638 PTC (mean age, 51 y); cT1 cN0, 26% T3, 57% N1 | 100 | TNM | Cancer death,1 (< 0.1%); recurrences, 62 (2%) (4 M1) | Tg + imaging (CRx, US, CT scan) (7.5 y, range 0.5–20) | 10-y DFS, 97%; 10-y DFS in N1 patients, 96%; recurrence rate, 2%; 1% thyroid bed recurrence in patients treated with lobectomy |
| Vaisman, 2011 (43) | RSC | 289 DTC (median age, 44 y) 10% T3, 7% N1a, 2% N1b | 100 | ATA | Recurrences, 8 (3%) | Tg + neck US (5 y, range 0.5–34) | Very low rate of recurrence: 2.3% with total thyroidectomy and 4% with lobectomy |
Abbreviations: CRx, chest radiography; DSS, disease-specific survival; NA, not available; RSC, retrospective single center.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
